Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, has appointed Rick Gonzalez Chief Executive Officer effective October 13. He will take over from Michael Goldberg, who was acting as Interim CEO. Gonzalez has more than 20 years of experience in the pharmaceutical industry, and most recently served as Vice President, Global Operations at Spectrum Pharmaceuticals, where he was responsible for designing and leading the globalization and commercialization strategy for international markets including Europe, Asia, Middle East and Latin America. Shares of Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) are trading within a 52-week range of $1.11 - $2.45."Rick brings an impressive depth of global commercial, operational and leadership experience in the biotechnology field including oncology and radiotherapy, which are highly relevant to Lymphoseek," said Gordon Troup, Chairman of the Board of Navidea. "His extensive expertise across all aspects of product commercialization together with his proven track record of success will be invaluable to the growth of the Company as we continue to advance the commercialization of Lymphoseek and demonstrate the value of our pipeline."Stag Industrial Inc (NYSE:STAG) said it priced of an underwritten public offering of common stock at a price to the public of $21.20 per share. The size of the offering has been upsized from 5,000,000 shares to 5,500,000 shares. The offering is expected to close on October 20, 2014. Stag Industrial Inc (NYSE:STAG) granted the underwriters of the offering a 30-day option to purchase up to an additional 825,000 shares of common stock. The company said it intends to use the net proceeds of the offering to repay indebtedness outstanding under its unsecured corporate revolving credit facility, to fund acquisitions currently under contract, for general working capital purposes, or a combination of the foregoing. STAG has been trading in a 52-week range of $19.28 to $25.19.West Pharmaceutical Services Inc. (NYSE:WST) said its Chairman and CEO Donald Morel plans to retire and cut the top end of its range for the full year. The company expects Q3 GAAP earnings of $0.43 a share, including a $0.01 per share charge for research, that's below the $0.44 analysts were expecting, if comparable, according to Capital IQ. It now sees its 2014 non-GAAP earnings in a range of between $1.77 and $1.82 mainly because of the strength of the U.S. dollar. In July, West Pharmaceutical Services Inc. (NYSE:WST) gave a 2014 range of $1.77 to $1.89. The Street consensus is $1.84 per share. Morel will step down in May next year. He has been with the company since 1992 and took over at CEO in 2002. The company has hired an executive search firm to hire a replacement. The shares recently traded at $44.31 with a 52-week spread of $39.11 - $51.12.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
